Ibrutinib Effective for Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia With 17p Deletion
The authors in this multicenter, single-arm, open-label study evaluated the safety and efficacy of ibrutinib in 145 patients with relapsed or refractory del17p chronic lymphocytic leukemia (CLL). Overall response rate at 27.6 months was 83%. Additionally, 2-year progression-free and overall survivals were 63% and 75%, respectively. Grade 3 or worse infection rate was 30%. The […]
